Chimeric Antigen Receptor Modified T Cells Infusion
Lymphoid Leukemia
Explore 13 assets in Lymphoid Leukemia →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Modality
Cell therapy
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03598179CT.gov XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lymphoid Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Chimeric Antigen Receptor Modified T Cells Infusion (this asset) | The First Affiliated Hospital with Nanjing Medical University | P2 | CCC · 53 |
| Fludarabine | Dartmouth-Hitchcock Medical Center | P4 | BBB |
| Ibrutinib | Loxo Oncology, Inc. | P4 | BBB |
| Busulfanum | Dartmouth-Hitchcock Medical Center | P4 | BB |
| Pirtobrutinib | Loxo Oncology, Inc. | P3 | BB |
| Lenalidomide | University of Wisconsin, Madison | P2 | BB |
| Rituximab | University of Washington | P2 | BB |
| Dexasone | St. Jude Children's Research Hospital | P2 | BB |
| Nivestim | Virginia Commonwealth University | P2 | B |
+42 more in the Lymphoid Leukemia cohort
Other indications for Chimeric Antigen Receptor Modified T Cells Infusion
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lymphoma | — | P2 | B · 61 |
| B-Cell Non-Hodgkin Lymphoma | — | P2 | B · 59 |
| HER2 Positive Breast Carcinoma | — | P1/2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Chimeric Antigen Receptor Modified T Cells Infusion in Lymphoid Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/chimeric-antigen-receptor-modified-t-cells-infusion-lymphoid-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →